skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension

Review

(3389) Views  (961) Full article downloads

Authors: Makoto Aihara

Published Date March 2010 Volume 2010:4 Pages 163 - 170
DOI: http://dx.doi.org/10.2147/OPTH.S6368

Makoto Aihara

Department of Ophthalmology, University of Tokyo School of Medicine, Tokyo, Japan

Abstract: An elevated intraocular pressure (IOP) is one of the most important risk factors for the development of glaucoma, which causes progressive optic neuropathy. Lowering IOP is currently the only therapeutic approach to the treatment of glaucoma. Tafluprost, a novel prostaglandin analogue, was recently launched onto the market as an ocular hypotensive agent. Tafluprost is potent in its affinity for the prostanoid FP receptor and in its intraocular lowering efficacy. Moreover, it enhances the ocular hemodynamics and has neuroprotective effects. Clinical studies have demonstrated its efficacy at decreasing intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Keywords: open-angle glaucoma, normal tension glaucoma, receptor affinity, intraocular pressure








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden
Considerations in glaucoma therapy: fixed combinations versus their component medications
Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma